The unique characteristics of MPO and EPO (rapid cidal action, broad-spectrum activity, and unique mechanism of action) are especially well-suited for preventing and treating the most serious types of nosocomial infections.

The incidence of nosocomial (or hospital-acquired) infections is estimated at 2 million cases annually, with 50% - 60% of those cases caused by antibiotic-resistant pathogens. The costs of nosocomial infections in the US are estimated at close to $6 billion annually with treatment costs for antibiotic-resistant nosocomial infections alone estimated at $1.3 billion dollars.

Incidence and resistant infections increase

Nosocomial infections, including surgical site infections, urinary tract infections, and ventilator-associated pneumonia, are increasing due to the aging of the population and treatment of older and more immunocompromised patients in hospital settings.

These infections are caused by a changing profile of pathogens, which are becoming increasingly resistant to available drugs. While bacterial resistance is the major threat, viral and fungal resistance is expected to become more important. Few, if any, drugs are available to effectively address these rapidly emerging problems. The Exoxemis MPO technology platform offers an alternative to traditional methods of preventing nosocomial infection without contributing to antimicrobial resistance.